Physician profile
Michelle Kerrigan
NPI 1447712054
$2,643.55
in general payments reported to CMS, 2019-2025
25 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,184 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.55 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.72 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $316.17 | 2024-2025 | Zoryve |
| Genzyme Corporation | $277.73 | 2024-2025 | |
| Janssen Biotech, INC. | $277.14 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $171.66 | 2024-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $170.26 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $150.56 | 2024-2025 | |
| Ucb, INC. | $123.53 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $122.46 | 2024-2025 | |
| Botanix Sb INC | $102.94 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $101.34 | 2024 | Vtama |
| Incyte Corporation | $63.24 | 2024-2025 | Opzelura |
| Pfizer INC. | $58.41 | 2024-2025 | |
| Leo Pharma INC. | $49.30 | 2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $37.87 | 2024 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.72 | 2024 | Sotyktu |
| Organon LLC | $32.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.65 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $23.20 | 2024 | |
| Biofrontera INC. | $22.42 | 2025 | Ameluz |
| Amgen INC. | $20.52 | 2024 | Otezla |
| Almirall LLC | $19.77 | 2025 | Seysara |
| Fresenius Kabi USA, LLC | $16.58 | 2024 | Idacio |
| Fidia Pharma USA INC. | $16.22 | 2025 | Triluron, Hymovis |
| Convatec INC. | $14.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.